Transaction Report:
(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) 1st Editorial Decision 27 September 2011
Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by three referees whose comments are shown below.
As you will see, they all found your study of potential interest. However, they have raised a certain number of issues that are explicitly reported in the reviews. Therefore, I would like to invite you to submit a revised version of the manuscript, fully addressing the comments of all three reviewers. I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal _____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
In this manuscript, Young et al. show that Myb-binding protein a (Mybbp1a) acts as repressor of skeletal myogenesis in C2C12 cells. Experiments of shRNA-mediated knockdown and overexpression demonstrate that Mybbp1a contributes to repress muscle gene expression in C2C12 myoblasts. ChIP experiments show Mybbp1a occupancy of some MyoD-target genes in undifferentiated myoblasts that is reduced during the differentiation process. shRNA-mediated knockdown of Mybbp1a reduces the chromatin recruitment of a number of known co-repressors of MyoD activity, including HDAC1 and 2 and Suv39h1, with a concomitant decrease in H3K92me and increase in acetyltransferase binding and H3K9 acetylation. The authors propose that during differentiation Mybbp1a levels decline by the parallel action of miR-546 and repression at the transcriptional level. I think that the biological effect of Mybbp1a on muscle differentiation described in this study is supported by solid evidence. This is, to my knowledge, the first study reporting on a role of Mybbp1a in the regulation of skeletal myogenesis. Given the potential interactions of Mybbp1a with a number of chromatin-modifying complexes (SWI/SNF and HDAC) implicated in the epigenetic control of muscle gene expression, this finding is novel and interesting. Unfortunately, this manuscript suffers from several problems and there are a number of issues (listed below) that the authors need to resolve in order to reach the publication standard of a high impact journal, such as EMBO J.
1) The experimental conditions are poorly described and in most of the figures there is no description of key information for an evaluation of the figures themselves. For instance, there is no mention of the antibodies used for ChIP and coIP, and quite disappointingly, it is reported the use of anti-SWI/SNF antibody ( Fig. 5 ) which in fact does not exists -there are many proteins that compose SWI/SNF complexes and vaguely referring to SWI/SNF instead of indicating the precise sub-unit reflects inaccuracy in experimental design and description. Moreover, the conditions used for the identification of genes up-and downregulated by Mybbp1a in C2C12 myoblasts ( Fig. 1) is largely incomplete and questionable; the authors first analyze the effect of Mybbp1a shRNA in myoblasts, without describing the culture conditions (are they undifferentiated or differentiating myoblasts?), then used a previously published expression gene profile from C2C12 myoblasts 6 days postdifferentiation to match their data. While it can be acceptable to merge microarray data with preexisting database, I do not understand why the authors do not simply analyze gene expression profile data in their own experimental conditions (GM and DM) used in Fig. 2F . Also, in ChIP experiments of Figs 4 and 5 it is not indicated the gene promoter analyzed -the reviewer could only assume that the analysis is performed on myogenin promoter, as described in Fig. 3 ). Other similar deficiencies were found along the manuscript.
2) An analysis in primary myoblasts (e.g. satellite cells) should be performed to support a physiological role of the miR-546-Mybbp1a network in skeletal myogenesis. At least the expression levels of Mybbp1a and miR-546 and the effect of Mybbp1a downregulation and antagomyrs should be evaluated in this context.
3) The mechanism responsible for Mybbp1a-mediated repression of MyoD target genes is not investigated. The correlation between Mybbp1a and HDAC-containing complexes reported by the authors appears of particular interest, especially when considering the potential interactions of Mybbp1a with co-repressory complexes, such as Ret-CoR and SWI/SNF. However, there is no specific mention of the type of SWI/SNF complex (activatory or repressory) that is recruited on muscle genes (see point 1) and no experiments attempting to establish a causal relationship between HDAC and Mybbp1a-mediated repression of muscle genes. I suggest that the authors explore this possibility a) by using HDAC inhibitors and/or HDAC1/2 siRNA to relieve the effect of Mybbp1a overexpression, and b) counter the effect of shRNA with overexpression of HDAC1/2. 4) ChIP and coIP experiments need proper controls. For ChIP, it should be shown a negative control for Mybbp1a binding. ChIP in fig. 3G needs to be performed in GM and DM. CoIP in Fig. 3F shows very "low resolution" bands and should be performed in both GM and DM conditions. 5) On page 11 the authors discuss their data by mentioning the similarities with EzH2 -the enzymatic component of PRC2 that represses MyoD-activated transcription in myoblasts. However, I do not see many similarities with Mybbp1a, with the exception of miR-targeting and transcriptional downregulation. The authors should acknowledge that Mybbp1a expression is still abundant in differentiated myotubes, while EzH2 completely disappears -see Fig. 2B .
Referee #2 (Remarks to the Author):
In this manuscript, Yang et al. have examined the role of the Mybbp1a protein in C2C12 myogenesis. Using shRNA to knock-down Mybbp1a in myoblasts, the authors performed microarrays and observed increased expression of genes involved in muscle development. Gene set enrichment analysis showed a significant overlap with genes up-regulated during myogenesis. Furthermore, many of these genes were found to be MyoD target genes. Interaction studies showed that MyoD does in fact interact with Mybbp1a. While MyoD targeting to the Myogenin gene did not require Mybbp1a, the association of HDAC proteins with the myogenin locus was reduced in the absence of Mybbp1a. This led to an increased level of acetylation at the gene, while a decrease in H3K9me2 was also observed, suggesting that Mybbp1a is likely stabilizing repressor complex association with the repressed genes. Examination of miRNAs as a potential mediator of Mybbp1a down regulation during differentiation identified miR-546 as a regulator of protein levels for this repressive factor in myoblasts. However the downregulation of Mybbp1a mRNA levels likely occurs through a decreased transcription of the gene. Based on these findings, the authors conclude that Mybbp1a is a transcriptional co-repressor in proliferating myoblasts whose expression is regulated through miR-546 to modulate the myoblast differentiation transition.
This an interesting manuscript that provides important new insight into the mechanism through which MyoD is acting to repress transcription in proliferative conditions. Mybbp1a is a novel corepressor of MyoD mediated transcription that appears to act as a scaffolding for the recruitment of other repressive enzymes to the target genes to prevent their expression. The authors have performed a thorough bioinformatic analysis to establish the interaction between MyoD and Mybbp1a, and the data is quite convincing showing that these two proteins work together to repress gene expression in proliferating myoblasts. However, several points need to be addressed:
1. ChIP experiments showing MyoD ( Figure 3H ) and Mybbp1a ( Fig 3D) binding at genes need negative controls -ie. genomic loci where the proteins are not bound, such that we can measure the increased recruitment at the muscle genes. 2. The ChIP-reChIP experiment shown in figure 3G is of poor quality. Firstly, it is not clear what the data is shown relative to. It should be presented as Percentage of input on the Y-axis. In addition, this experiment has to be much better controlled, showing a position in the genome where the proteins are not bound. The experiment should also show the IP using a non-specific antibody for the first IP, and MyoD in the second, as well as Mybbp1a in the first IP, and a non-specific antibody in the second. 3. It is not clear from the text (or the figure legend) whether microarrays on the Mybbp1a knockdowns were performed in growth or differentiation conditions. Please state this in the text of the result section. 4. The ChIP experiments in Figure 5 look at the association of co-repressor/co-activators/histone marks with muscle gene promoters. The text and figure legend don't show which promoter was used. This information needs to be made clear. 5. The fold cut-off >2 fold change (p< 0.05) was used to define the ~500 genes that were upregulated upon Mybbp1a knock-down. However, to obtain significant overlap with the genes that change their expression during muscle differentiation, this number was reduced to 1.5 fold. Was the stringency of calling an up-regulated gene reduced because the overlap was not sufficient for statistical significance. If 1.5 fold is used for the GSEA analysis, the p-value for the longer list of up-regulated genes from the microarrays should be provided and the number of genes used to obtain an overlap of 153 genes in this analysis should also be provided. 6. On page 5, page 29, it is stated that "....Mybbp1a-depleted myoblasts may enter a phase of cell cycle cessation and early differentiation...". This comment requires testing through BrdU incorporation studies, or it should be removed from the text. The slight activation of muscle genes in growth conditions is not sufficient to support this statement on cell cycle exit. 7. On page 6, the Hsiao 2009 paper is not the proper reference for the plasmids used in your luciferase assays. Find the proper references for these plasmids, or don't reference them at all. They are widely used in the muscle field, but certainly didn't originate in the Hsiao paper. 8. Page 11, line 22, "sate" should read "state" 9. Page 11, line 26, "such role" should read "such a role"
Referee #3 (Remarks to the Author):
In this manuscript, the authors examine the role of Mybbp1a in myogenesis using a combination of global and gene-specific expression studies, chromatin immunoprecipitation (ChIP), and Mybbp1a overexpression and knock-down experiments. Specifically, the authors provide evidence that Mybbp1a negatively regulates myoblast differentiation by interacting with MyoD and repressive chromatin modifiers at muscle-specific gene promoters to epigenetically silence these genes. Upon differentiation, Mybbp1a is downregulated by miR-546, allowing for the subsequent transcriptional activation of genes important for muscle differentiation.
These findings are of high interest to those in the field of muscle biology, as well as providing a mechanistic framework for understanding how Mybbp1a may be functioning in other systems. The experiments presented, for the most part, are well controlled and support the arguments of the authors. There are no major concerns with the manuscript, however, a number of minor points should be addressed to strengthen the paper before publication.
1. In Figure 1B , it is unclear as to the significance of the change in shading of the last two categories, 'Neurogenesis in general' and 'Blood coagulation'. Are the categories with dark orange statistically significant while these last two are not? This should be addressed in the Figure legend. Figures 2F and 2G, it is unclear if all of the genes were found to be upregulated when Mybbp1a was knocked-down. The data provided in Supplementary Table S1 does not include genes MLC9 and Pyr1. This referee is unclear as to what Pyr1 could be and would guess that MLC9 is Myl9. If the latter is true, it would be helpful to consistently label the gene, with the preference going to Myl9, since MLC9 is not in Pubmed. It would also be helpful to have one gene that did not change in expression, especially in the DM-ctrl and DM-si-Mybbp1a samples in Figure 2F . Likewise, this gene should be shown to be unaffected by the Mybbp1a overexpression shown in Figure 2G .
For the genes subjected to quantitative RT-PCR analysis and depicted in
3. In Figure 5 , it is unclear what promoter or promoters are being analyzed in the ChIP experiments presented. In the results section of the manuscript and the Figure legend, it states that muscle promoters (plural) are being interrogated. Given the other analysis presented in the manuscript, it is most likely that only one gene promoter is being looked at, though what this gene could be is not stated anywhere. This needs to be clarified.
4. In Figure 7 , the data would be more convincing if a muscle-specific gene was shown to have increased Pol II occupancy by ChIP over the time course of the 0-48 hours in differentiation media. This would control for the possibility, for whatever technical reason, that the Pol II ChIP was less effective in general over the course of the experiment.
5. There are number of typographical errors in the manuscript that should be corrected, and while the manuscript is very readable in its current form, there are a number of grammatical errors in the paper that detract from the overall quality of the presentation. >We thank the reviewer for this accurate summation of the paper and the favorable comments. We have addressed the reviewer's concerns and revised the manuscript accordingly (see below for responses).
1) [1a] The experimental conditions are poorly described and in most of the figures there is no description of key information for an evaluation of the figures themselves. For instance, there is no mention of the antibodies used for ChIP and coIP, and quite disappointingly, it is reported the use of anti-SWI/SNF antibody (Fig. 5) which in fact does not exists -there are many proteins that compose SWI/SNF complexes and vaguely referring to SWI/SNF instead of indicating the precise sub-unit reflects inaccuracy in experimental design and description.
>We apologized for this casual error of ours that has now been readily corrected. We have added in Figure 5 and its legend (on p. 27) the specific protein component (Brg1) to the description of the SWI/SNF complex. This information is also now included in the Results (first paragraph of p. 9) and the Materials and Methods ("Reagents and antibodies", p. 16). Information for the antibodies used in ChIP and coIP experiments were detailed in the Materials and Methods ("Reagents and antibodies", p. 16).
[1b] Moreover, the conditions used for the identification of genes up-and downregulated by Mybbp1a in C2C12 myoblasts (Fig. 1) Fig. 2F .
>Thank you for pointing this out as we were too casual and left out the precise conditionsmicroarray analysis was performed on the control and knockdown C2C12 cells that were cultured under the growth/proliferation condition (GM). We have now added this information to the Results (p. 5, "Identification of putative Mybbp1a target genes by global gene expression profiling") as well as the Materials and Methods sections (p. 14, "Microarray experiments and statistical analysis").
The title of the Figure 1 legend is also modified to "Identification of Mybbp1a target genes in proliferating C2C12 cells by microarray analysis." As results from this analysis revealed an enrichment of up-regulated genes with functions in myogenesis, we thus suspected that Mybbp1a might act as a repressor of the myogenic program. The cross-sample bioinformatics comparison (Fig. 1, C & D) was subsequently performed to test this hypothesis. We did not use microarray approach to assess gene expression under the DM condition; instead, real-time RT-PCR assays were done to confirm expression of the inferred target genes under both GM and DM conditions, as shown in Figure 2F . Fig. 3 ). Other similar deficiencies were found along the manuscript.
[1c] Also, in ChIP experiments of Figs 4 and 5 it is not indicated the gene promoter analyzed -the reviewer could only assume that the analysis is performed on myogenin promoter, as described in
>We apologize that this was not clear in the previous manuscript, and have now made sure that this information -the MyoG promoter -is clearly stated in the Results (pages 8-9, "RNAi depletion of Mybbp1a alters epigenetic status of muscle gene promoter") and Figure 5 legend (p. 27).
2) An analysis in primary myoblasts (e.g. satellite cells) should be performed to support a physiological role of the miR-546-Mybbp1a network in skeletal myogenesis. At least the expression levels of Mybbp1a and miR-546 and the effect of Mybbp1a downregulation and antagomyrs should be evaluated in this context.
>We agree with the reviewer that an analysis using primary myoblasts should provide further physiological evidence for the miR-546-Mybbp1a network in skeletal myogenesis. We have now carried out a new series of experiments, based on the reviewer's suggestions, using primary myoblasts isolated from neonatal mice (please refer to the new section of "Isolation and culture of mouse primary myoblasts" in Supplementary Methods for technical details). The new results, which are in line with our observations with the C2C12 cell line, are now shown in the new Supplementary Figure 6 and described in the Results ("miRNA-546 targets Mybbp1a in differentiating myoblast and enhances muscle differentiation", pages 9-10).
3) The mechanism responsible for Mybbp1a-mediated repression of MyoD target genes is not investigated. The correlation between Mybbp1a and HDAC-containing complexes reported by the authors appears of particular interest, especially when considering the potential interactions of Mybbp1a with co-repressory complexes, such as Ret-CoR and SWI/SNF. However, there is no specific mention of the type of SWI/SNF complex (activatory or repressory) that is recruited on muscle genes (see point 1) and no experiments attempting to establish a causal relationship between HDAC and Mybbp1a-mediated repression of muscle genes. I suggest that the authors explore this possibility a) by using HDAC inhibitors and/or HDAC1/2 siRNA to relieve the effect of Mybbp1a overexpression, and b) counter the effect of shRNA with overexpression of HDAC1/2.
>We have further addressed the mechanistic aspect of the Mybbp1a-HDAC1/2 interaction as suggested by the reviewer and provided additional evidence to strengthen the connection between HDAC1/2 and the Mybbp1a-mediated muscle gene repression. These new findings are now shown as the new Figures 4D & 4E , with a new paragraph being incorporated in the Results for data description and interpretation (p. 8). With regard to the questions raised by the reviewer, our new data demonstrated that 1) RNAi knockdown of HDAC1/2 abolished the gene repression exerted by Mybbp1a overexpression, and 2) overexpression HDAC1/2 had no effect on the extent of gene upregulation in the absence of Mybbp1a. Concerning the latter point, the lack of effect by overexpressed HDAC1/2 in the absence of Mybbp1a may be explained by our observation that promoter recruitment of HDAC1/2 required Mybbp1a (Fig. 4 , B & C). Fig.  3F shows very "low resolution" bands and should be performed in both GM and DM conditions. >We apologize for not being very clear on the presentation of these data. All ChIP experiments shown in this report, including the ChIP-reChIP assay, were done with the control IgG as well as the specific antibodies. As indicated in the respective legends as well as the Materials and Methods ("Chromatin immunoprecipitation (ChIP) and real-time PCR analysis", p. 19), all results were corrected for nonspecific binding to IgG (whose values were considered as 1 and not shown in the bar graphs). In addition, the negative control of a non-binding genomic locus (the GAPDH promoter) for the Mybbp1a (Fig. 3, D & G) and MyoD (Fig. 3 , G & H) ChIP's are now included in the respective figures. We also incorporated statements to this effect in the Results ("Mybbp1a interacts with MyoD at the chromatin regulatory region of transcriptionally inactive muscle genes and inhibits MyoD-mediated transactivation", p. 7). The coIP (Fig. 3F) and ChIP (Fig. 3G ) experiments were repeated in both GM and DM conditions; and more definite results of the Western blot analysis are now shown in Figure 3F . With regard to these GM vs. DM comparisons, we have also included descriptions for these findings in the corresponding Results section (p. 7). Fig. 2B .
4) ChIP and coIP experiments need proper controls. For ChIP, it should be shown a negative control for Mybbp1a binding. ChIP in fig. 3G needs to be performed in GM and DM. CoIP in

5) On page 11 the authors discuss their data by mentioning the similarities with
>Per the reviewer's suggestion, we have rephrased the statement at the beginning of the second paragraph of the Discussion to: "Our results indicate that the expression of Mybbp1a in proliferating myoblasts is immediately down-regulated upon differentiation induction. While Mybbp1a is still present to a certain extent in the differentiated myotubes (Fig. 2B) 
the association of HDAC proteins with the myogenin locus was reduced in the absence of Mybbp1a. This led to an increased level of acetylation at the gene, while a decrease in H3K9me2 was also observed, suggesting that Mybbp1a is likely stabilizing repressor complex association with the repressed genes. Examination of miRNAs as a potential mediator of Mybbp1a down regulation during differentiation identified miR-546 as a regulator of protein levels for this repressive factor in myoblasts. However the downregulation of Mybbp1a mRNA levels likely occurs through a decreased transcription of the gene. Based on these findings, the authors conclude that Mybbp1a is a transcriptional co-repressor in proliferating myoblasts whose expression is regulated through miR-546 to modulate the myoblast differentiation transition.
This an interesting manuscript that provides important new insight into the mechanism through which MyoD is acting to repress transcription in proliferative conditions. Mybbp1a is a novel corepressor of MyoD mediated transcription that appears to act as a scaffolding for the recruitment of other repressive enzymes to the target genes to prevent their expression. The authors have performed a thorough bioinformatic analysis to establish the interaction between MyoD and Mybbp1a, and the data is quite convincing showing that these two proteins work together to repress gene expression in proliferating myoblasts.
>Thank you for an accurate summary of the report and all the positive comments.
However, several points need to be addressed: Figure 3H ) and Mybbp1a (Fig 3D) binding at genes need negative controls -ie. genomic loci where the proteins are not bound, such that we can measure the increased recruitment at the muscle genes.
ChIP experiments showing MyoD (
>Thank you. All ChIP experiments shown in this report, including the ChIP-reChIP assay, were done with the control IgG as well as the specific antibodies. As indicated in the respective legends as well as the Materials and Methods ("Chromatin immunoprecipitation (ChIP) and real-time PCR analysis", p. 19), all results were corrected for nonspecific binding to IgG (whose values were considered as 1 and not shown in the bar graphs). In addition, the negative control data of a nonbinding genomic locus (the GAPDH promoter) for the Mybbp1a (Fig. 3, D & G) and MyoD (Fig. 3 , G & H) ChIP's are now included in the respective figures. We also incorporated statements to this effect in the Results ("Mybbp1a interacts with MyoD at the chromatin regulatory region of transcriptionally inactive muscle genes and inhibits MyoD-mediated transactivation", p. 7). figure 3G is >As mentioned in the previous point, all ChIP experiments shown in this report, including the ChIPreChIP assay, were done with the control IgG as well as the specific antibodies. As indicated in the respective legends as well as the Materials and Methods ("Chromatin immunoprecipitation (ChIP) and real-time PCR analysis", p. 19), all results were corrected for nonspecific binding to IgG (whose values were considered as 1 and not shown in the bar graphs). In addition, the control of a nonbinding genomic locus (the GAPDH promoter) for the ChIP analysis is incorporated, as shown in the modified Figure 3G . Finally, as suggested by the other reviewer, we also included in the same figure the new results from the sequential ChIP done under the DM condition, which may serve as another control for the specific promoter binding of Mybbp1a under the GM condition. To reflect these new data, we modified the Results in the corresponding section (p. 7).
The ChIP-reChIP experiment shown in
It is not clear from the text (or the figure legend) whether microarrays on the Mybbp1a knockdowns were performed in growth or differentiation conditions. Please state this in the text of the result section.
>We apologize for the lack of precise description for this particular experimental condition. This microarray analysis was done on Mybbp1a-knockdown (and control) C2C12 cells cultured under growth condition. We have now added this information to the Results (p. >We have added the requested information to the revised manuscript (second paragraph on p. 5). As we performed the cross-samples comparison (Mybbp1a knockdown in GM vs. myoblast differentiation), we took into consideration the extent to which Mybbp1a candidate targets might undergo de-repression in the absence of differentiation cues, which likely was limited under the experimental condition (i.e. growth medium). We thus relaxed the stringency of fold-change requirement to allow a better representation of gene expression signatures. >We thank the reviewer for pointing out the significance of our work and for the favorable comments. We have addressed these concerns as outlined below. Figure 1B >For this type of analysis, we consider only P-value <0.05 as "significant" enrichment (there was initially a total of 18 processes/networks that satisfied this criterion, with only the top 10 shown in Figure 1B ). Dark orange bars further denote processes with False Discovery Rate (FDR) <0.05, whereas the last two categories (denoted by light orange bars) did not satisfy this higher cut-off in significance. To avoid further confusion, we have now revised the figure to exclude the last two categories. We also provided statistical significance measures in the corresponding figure legend to clarify this result (p. 24). Figures 2F and 2G Figure 2F . Likewise, this gene should be shown to be unaffected by the Mybbp1a overexpression shown in Figure 2G .
In
For the genes subjected to quantitative RT-PCR analysis and depicted in
>We apologize for the casual error in gene nomenclature, which has been readily corrected in the revision. Myl9 was indeed what we intended to show, as mentioned by the reviewer, while Pyr1 should actually be Ryr1. With regard to the gene expression profiling experiments, all the genes shown in Figure 2F were found to be upregulated in the si-Mybbp1a vs. control comparison. As suggested by the reviewer, we have included the results of two unrelated genes (Amy1 and Morf4l2), whose expression was not altered by Mybbp1a, as shown by both the microarray and real-time RT-PCR assays. The new data are now incorporated in the new Supplementary Figure S1 and mentioned the corresponding Results section (first paragraph of page 6). Figure 5, >We apologize that this was not clear in the previous manuscript, and have now made sure that this information -the MyoG promoter -is clearly stated in the Results (pages 8-9, "RNAi depletion of Mybbp1a alters epigenetic status of muscle gene promoter") and Figure 5 legend (p. 27). Figure 7, >We have now corrected these typos as well as others we have found in the manuscript. We have revised the whole manuscript carefully and asked colleagues who are skilled authors of English language papers to check the English.
In
Pre-acceptance letter 20 January 2012
Thank you for submitting your revised manuscript to our editorial office.
We are pleased to let you know that your manuscript will be formally accepted for publication pending final amendments:
We have noticed that the Material and Methods section does not contain any paragraph regarding Statistical Analysis. Please provide such information according to the guideline as follow:
Statistical analysis All statistical analyses performed in the work must be clearly described, including the name of the test performed and the number (n) of independent experiments underlying each analysis. Authors must justify the use of a particular test and explain whether their data conform to the assumptions of the tests.
We would really appreciate if you could send back a word file of the final article text via e-mail.
Congratulations on your interesting work! Yours sincerely Editor The EMBO Journal
